A 55-year-old man with CKD Stage 4 (eGFR 22 mL/min/1.73m²) due to IgA nephropathy is referred for pre-emptive kidney transplant evaluation. His serum calcium is 8.2 mg/dL, phosphate 5.8 mg/dL, and parathyroid hormone (PTH) is 380 pg/mL. Which of the following best describes the pathophysiology of secondary hyperparathyroidism in this patient?

Explanation

## Pathophysiology of Secondary Hyperparathyroidism in CKD **Key Point:** Secondary hyperparathyroidism (2° HPT) in CKD results from chronic stimulation of parathyroid tissue by hypocalcemia, hyperphosphatemia, and low calcitriol, leading to parathyroid hyperplasia and impaired suppression by calcium and calcitriol. ### Mechanism: 1. **Early CKD:** Declining GFR → ↓ calcitriol (1,25-dihydroxyvitamin D₃) synthesis and ↑ FGF23. 2. **Loss of PTH suppression:** Low calcitriol → reduced inhibition of PTH gene expression. 3. **Hyperphosphatemia:** Directly stimulates PTH secretion AND further suppresses calcitriol. 4. **Hypocalcemia:** Stimulates PTH secretion (compensatory). 5. **Parathyroid hyperplasia:** Chronic stimulation → increased parathyroid mass, reduced calcium-sensing receptor (CaSR) expression, and **impaired negative feedback**. 6. **Result:** PTH becomes increasingly resistant to suppression by calcium and calcitriol (tertiary-like features may develop). **Clinical Pearl:** The hallmark of 2° HPT is **parathyroid hyperplasia with loss of suppressibility**, distinguishing it from primary HPT (adenoma) and tertiary HPT (autonomous nodule formation). **High-Yield:** FGF23 is an early marker of mineral metabolism dysregulation; it rises before serum phosphate increases, making it a sensitive early indicator of CKD-MBD. **Mnemonic:** **HyPo-Cal-Phos** — Hyperplasia from chronic stimulation by hypocalcemia, low calcitriol, and hyperphosphatemia.